Drug Trial Radar · NCT04752813
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 22, 2022
Primary completion
Aug 25, 2026
Study completion Aug 26, 2030
Sponsor
- Lead sponsor
- BPGbioIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Conditions
- Glioblastoma
- Glioblastoma Multiforme
Interventions
BPM31510Drug
Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.
Vitamin K1Other
Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg subcutaneously prior to the beginning of each week of BPM31510 therapy.
Temozolomide (TMZ)Drug
After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for up to 12 cycles post BPM31510 treatment.
RadiationRadiation
After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy will be assessed by subject progression free survivalTime frame: 6 months and 12 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Stanford University Cancer Center
Palo Alto, California
Sansum Clinic
Santa Barbara, California
Dana Farber Cancer Institute
Boston, Massachusetts
Valley Health
Ridgewood, New Jersey
Mount Sinai Hospital
New York, New York
Texas Oncology
Austin, Texas
UT Health San Antonio Mays Cancer Center
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Inova
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.